drug development Related News
XPhyto: A leader in innovating psychedelic drugs
XPhyto Therapeutics Corp is exploring the role that psychedelic pharmaceutical drugs can play in combatting mental health conditions.
It’s a staggering statistic. A full 11%...
Reducing cardiovascular and cerebrovascular deaths with AstraZeneca
AstraZeneca’s recent THALES Phase III trial has demonstrated the efficacy of the drug Brilinta for reducing the risk of major cardiovascular events such as...
Innovative drug delivery devices to increase the quality of life of diabetic patients
Ypsomed’s innovative mylife Diabetescare offers patients, pharmacies, and clinics access to high-quality, and reliable drug delivery devices for those living with diabetes.
Ypsomed creates drug...
How data science is driving innovations in medical biotechnology
In this article, Ramya Sriram, digital content manager at freelance platform for scientists, Kolabtree, explains how data science is driving innovations in medical biotechnology.
It...
Artificial enzyme could lead to new Parkinson’s disease treatment
A team of researchers have created an artificial enzyme that could help form a new treatment for the neurodegenerative Parkinson’s disease.
The team from Johns...
Treating depression by ‘erasing’ neuroplasticity damage caused by stress
Researchers have used epigenetic modulators in an attempt at ‘erasing’ damage to neuroplasticity caused by stress, showing that acute intervention in epigenetic mechanisms produces...
Treating brain disorders with new nanoparticle drug delivery system
A new nanoparticle drug-delivery system could help scientists overcome the long-standing problem of delivering therapeutics across the blood-brain barrier and into the brain.
Progress has...
Long-acting injectable HIV treatment approved in Europe
The European Commission has approved marketing authorisation for the first long-acting injectable treatment for HIV to be made available in Europe.
REKAMBYS, a rilpivirine injection...
European Commission approves contract for potential COVID-19 vaccine
The European Commission has approved a contract with Moderna to secure access to a potential COVID-19 vaccine.
The contract will be the sixth one made...
COVID-19 vaccine Phase III clinical trials to begin in UK
Phase III clinical trials for a COVID-19 vaccine are set to begin in the UK and will involve 6,000 volunteers from across the country.
Global...
Potential lupus treatment reduces organ damaging corticosteroid use
The treatment anifrolumab has been found to reduce lupus flares whilst allowing for patients to reduce the use of corticosteroids that can cause organ...
World Health Organization addresses drug safety during COVID-19
The World Health Organization is highlighting the need for international drug safety monitoring during COVID-19.
For medicines to work safely, having strong systems in place...
Innovation and drug development with Tetra Bio-Pharma
Tetra Bio-Pharma executives speak out about building a cannabinoid pharmaceutical company.
For this article, we sat down for a virtual fireside chat with some key...
Deploying AI in drug discovery
AI healthcare upstart Aladdin continues to develop best-in-class AI technologies to advance and accelerate new breakthroughs in drug discovery.
In October 2020, UK-based healthcare technology...
Farxiga granted Breakthrough Therapy Designation by FDA
Farxiga has been given Breakthrough Therapy Designation by the Food and Drug Administration (FDA) for patients with chronic kidney disease.
Farxiga has recently shown encouraging...
First medicine to prolong survival in patients with chronic kidney disease
In a groundbreaking Phase III trial AstraZeneca’s Farxiga has shown reduction in the risk of kidney failure and cardiovascular or renal death in patients...
Investigation launched after Home Office psilocybin rescheduling response
MP Crispin Blunt has launched an economic investigation following the Home Office’s response to the recent call for the rescheduling of psilocybin.
The non-profit Conservative...
First at-home treatment for spinal muscular atrophy approved by FDA
The first at-home, orally administered treatment for spinal muscular atrophy has been approved by the US Food and Drug Administration (FDA).
The treatment – Evrysdi...
The UK Vaccine Taskforce: securing access to vaccines
Kate Bingham, Chair of the UK Vaccine Taskforce, discusses the three goals of the taskforce.
The UK Vaccine Taskforce has three key goals: to secure...
Cannabinoid therapies aim to address unmet medical needs
Oxford Cannabinoid Technologies (OCT) has appointed a new Chief Scientific Officer to help deliver cannabinoid therapies for unmet medical needs.
Dr Valentino Parravicini, PhD will...
